Tanaproget
NSP-989, NSP-989 COMBO, Tanaproget COMBO, WAY-166989
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Oral
-
Intended Duration:
- Short-Acting
- Development Stage: Phase II
- Developer(s)/researcher(s): Wyeth Research, Ligand Pharmaceuticals, Inc.
Details
- API: Tanaproget
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Inactive Materials: Undetermined
- Regimen: 1 Pill/Day
- MPT: Not Potential MPT
Product Status
No evidence of subsequent development - product is not listed on Ligand's website
History
2010: Ligand receives $1M upfront payment from Pfizer for sublicense of tanaproget, tissue-selective, non-steroidal contraceptive progesterone receptor agonist.